Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INBX NASDAQ:PRTC NASDAQ:REPL OTCMKTS:TBUFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx Biosciences$27.69-6.4%$23.42$10.81▼$30.23$401.06M0.31106,187 shs73,861 shsPRTCPureTech Health$15.76-5.9%$18.08$13.30▼$24.99$380.29M1.114,558 shs1,571 shsREPLReplimune Group$5.96+2.4%$6.89$2.68▼$17.00$465.14M0.513.93 million shs1.23 million shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx Biosciences+1.65%+7.10%+40.46%+101.50%+94.61%PRTCPureTech Health+2.46%+1.96%-2.47%-12.60%-18.76%REPLReplimune Group-3.64%-1.36%+10.02%-40.49%-44.73%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINBXInhibrx Biosciences$27.69-6.4%$23.42$10.81▼$30.23$401.06M0.31106,187 shs73,861 shsPRTCPureTech Health$15.76-5.9%$18.08$13.30▼$24.99$380.29M1.114,558 shs1,571 shsREPLReplimune Group$5.96+2.4%$6.89$2.68▼$17.00$465.14M0.513.93 million shs1.23 million shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINBXInhibrx Biosciences+1.65%+7.10%+40.46%+101.50%+94.61%PRTCPureTech Health+2.46%+1.96%-2.47%-12.60%-18.76%REPLReplimune Group-3.64%-1.36%+10.02%-40.49%-44.73%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINBXInhibrx Biosciences 2.00HoldN/AN/APRTCPureTech Health 0.00N/AN/AN/AREPLReplimune Group 2.10Hold$6.509.08% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBUFF, REPL, PRTC, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform7/30/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight7/23/2025REPLReplimune GroupBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$17.00 ➝ $3.007/23/2025REPLReplimune GroupBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Underperform$27.00 ➝ $2.007/23/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/22/2025REPLReplimune GroupLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/22/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/22/2025REPLReplimune GroupJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$31.00 ➝ $6.007/22/2025REPLReplimune GroupLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$21.00 ➝ $3.007/22/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$19.00 ➝ $9.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINBXInhibrx Biosciences$1.40M286.47$110.75 per share0.25$9.23 per share3.00PRTCPureTech Health$4.83M78.73$2.29 per share6.89$17.04 per share0.92REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/AREPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TBUFF, REPL, PRTC, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINBXInhibrx BiosciencesN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINBXInhibrx Biosciences1.454.984.98PRTCPureTech HealthN/A8.499.33REPLReplimune Group0.216.946.94TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINBXInhibrx Biosciences82.46%PRTCPureTech Health0.04%REPLReplimune Group92.53%TBUFFTribute Pharmaceuticals CanadaN/AInsider OwnershipCompanyInsider OwnershipINBXInhibrx BiosciencesN/APRTCPureTech Health5.30%REPLReplimune Group5.20%TBUFFTribute Pharmaceuticals CanadaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINBXInhibrx Biosciences16614.49 millionN/AOptionablePRTCPureTech Health10024.13 million22.85 millionNot OptionableREPLReplimune Group21078.06 million74.00 millionOptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTBUFF, REPL, PRTC, and INBX HeadlinesRecent News About These CompaniesSimone Biles pays tribute to husband Jonathan Owens with tiny new tattooSeptember 21, 2024 | pagesix.comPKid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?September 14, 2024 | snopes.comSTRANSFORMERS ONE - Advance Screening & Prize Pack ContestSeptember 12, 2024 | tribute.caTCate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”September 11, 2024 | deadline.comDInside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar SnubsSeptember 11, 2024 | variety.comVTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comTop country stars honor Toby Keith in a new special. Here's how to watchSeptember 1, 2024 | today.comT‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tributeJuly 31, 2024 | pagesix.comPValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comAbout Tribute.caApril 1, 2024 | tribute.caTMacGregor: A Remembrance Day tribute to Canada's Korean War veteransNovember 13, 2023 | ottawacitizen.comOChurch Under Fire: Canada's War on Christianity - CastOctober 25, 2023 | tribute.caTTerry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore iconAugust 27, 2023 | sportingnews.comSRon Canada Biography & MoviesJuly 23, 2023 | tribute.caTWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comAlberta tattoo artists pay tribute to laser removal expert who helped people move past traumaApril 29, 2023 | cbc.caMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comHumboldt holds tribute five years after deadly bus crashApril 8, 2023 | thestar.comTPaul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock deathApril 3, 2023 | thesun.co.ukGamer Crochets Destiny 2 Tribute to Zavalla Actor Lance ReddickApril 3, 2023 | gamerant.comGNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025TBUFF, REPL, PRTC, and INBX Company DescriptionsInhibrx Biosciences NASDAQ:INBX$27.69 -1.90 (-6.43%) Closing price 03:59 PM EasternExtended Trading$27.56 -0.13 (-0.46%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.PureTech Health NASDAQ:PRTC$15.76 -0.99 (-5.91%) Closing price 03:59 PM EasternExtended Trading$16.03 +0.27 (+1.71%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Replimune Group NASDAQ:REPL$5.96 +0.14 (+2.39%) Closing price 03:59 PM EasternExtended Trading$5.83 -0.13 (-2.16%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
